Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anatibant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 known ✓ | P30411 | 4/20 | 1.00 |
| ▸ | RORC | P51449 | 16/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anatibant SCHEMBL6945415 | 1.00 | BDKRB2 (1.00) | BDKRB2RORC | |
| Anatibant SCHEMBL29379305 | 1.00 | BDKRB2 (1.00) | BDKRB2RORC | |
| Anatibant SCHEMBL1649974 | 1.00 | BDKRB2 (1.00) | BDKRB2RORC | |
| Anatibant SCHEMBL8045259 | 0.99 | BDKRB2 (0.99) | BDKRB2RORC | |
| Anatibant SCHEMBL29711321 | 0.99 | BDKRB2 (0.98) | BDKRB2RORC | |
| Anatibant SCHEMBL8045426 | 0.99 | BDKRB2 (0.98) | BDKRB2RORC | |
| SCHEMBL6948870 | 0.99 | BDKRB2 (0.98) | BDKRB2RORC | |
| SCHEMBL6950081 | 0.98 | BDKRB2 (0.96) | BDKRB2RORC | |
| Hydrochloric Acid SCHEMBL8040359 | 0.98 | BDKRB2 (0.95) | BDKRB2RORC | |
| SCHEMBL6953304 | 0.98 | BDKRB2 (0.95) | BDKRB2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | BDKRB2 2339/4885RORC 553/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | BDKRB2 3277/4885RORC 2460/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | BDKRB2 3277/4885RORC 2460/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | BDKRB2 3530/4885RORC 2859/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | BDKRB2 3530/4885RORC 2859/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | BDKRB2 3530/4885RORC 2859/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | BDKRB2 2693/4885RORC 611/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | BDKRB2 2229/4885RORC 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.